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To the Editor,
In newborns with atypical genitalia, suspicious for a dis-
order of sex development (DSD), measurement of testos-
terone is an essential part in the diagnostic workup [1].
Previously, direct testosterone immunoassays have 
proven to be inaccurate because they tend to overestimate 
testosterone concentrations in the lower ranges, such as 
those in females and infants [2], but specifically also in 
neonates [3, 4]. Based on the concern for cross-reactivity 
in neonatal samples, the recently revised UK guideline on 
the initial evaluation of DSD from the UK Society for Endo-
crinology recommends that steroids in plasma or serum 
are measured by either LC-MS/MS or immunoassays after 
organic solvent extraction [1]. The use of LC-MS/MS was 
considered superior by a recent consensus meeting of DSD 
experts across Europe, although validation and quality 
control remain challenging [5].
The accuracy of testosterone immunoassays 
has improved significantly with the introduction of 
second-generation testosterone assays [2]. These second- 
generation assays generally show high correlation coef-
ficients with LC–MS/MS data, at both low and high 
concentrations [2, 6].
The aim of the present study was to assess whether 
second-generation immunoassays are able to determine 
testosterone concentrations in neonates accurately. We 
compared plasma testosterone concentrations measured 
with two widely used second-generation immunoassays 
to those measured with LC-MS/MS in infants directly after 
birth up until 6 months of age.
For measurements of plasma testosterone, leftover 
heparin plasma samples were anonymously selected from 
infants born at term (≥37 weeks) with normal external gen-
italia. Ages varied between the day of birth and 6 months. 
For comparison of the Architect® second-generation tes-
tosterone assay with LC-MS/MS, samples from 33 male and 
45 female neonates were collected at the VU University 
medical center. For comparison of the Elecsys® second-
generation testosterone assay with LC-MS/MS, samples 
from 16 male and 4 female neonates were collected at the 
Radboud University medical center. For additional analy-
sis of 11β-hydroxytestosterone, a metabolite with known 
high cross-reactivity in both testosterone immunoassays, 
leftover samples were used from male (n = 27) and female 
(n = 16) infants born at term aged 0–2 days or >6 months. 
Use of anonymized leftover samples is approved by the 
Medical Ethics Committees of  the respective University 
Medical Centers.
The total plasma testosterone concentration was 
measured with an automated chemiluminescent micro-
particle immunoassay, the Architect® second-generation 
testosterone assay (Abbott Diagnostics, Abbott Park, 
IL, USA) [2, 6], or with an automated chemiluminescent 
microparticle immunoassay, the Elecsys® second-genera-
tion testosterone assay (Roche Diagnostics Ltd., Rotkreuz, 
Switzerland [7]. In all samples, total testosterone was also 
measured with isotope-dilution LC–MS/MS as described 
previously by our research group [6].
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Table 1 shows the median concentrations and ranges of 
testosterone in plasma in boys and girls from all age catego-
ries up until 6 months of age measured with the  Architect® 
second-generation immunoassay and LC-MS/MS. In boys 
(n = 10), the median (range) plasma testosterone con-
centration during the first 3  days of life was 4.7  nmol/L 
(2.1–13.5  nmol/L) and 2.0  nmol/L (1.1–8.7  nmol/L) when 
measured with the Architect® second-generation immu-
noassay and LC-MS/MS, respectively. In girls of the same 
age (n = 8), the median (range) plasma testosterone con-
centration was 2.3 nmol/L (0.7–5.8 nmol/L) and 0.1 nmol/L 
(0.1–0.3 nmol/L) when measured with the Architect® sec-
ond-generation immunoassay and LC-MS/MS, respectively.
In a second cohort (16 male and four female samples), 
testosterone concentrations were measured with the 
Elecsys® second-generation testosterone immunoassay 
and compared to LC-MS/MS. In boys (n = 8), median (range) 
plasma testosterone concentrations during the first 3 days 
of life were 12  nmol/L (9.3–22  nmol/L) and 5.2  nmol/L 
(1.7–18 nmol/L) when measured with the Elecsys® second-
generation immunoassay and LC-MS/MS, respectively. In 
girls of the same age (n = 2), median (range) plasma tes-
tosterone concentrations were 10 nmol/L (7.6–13 nmol/L) 
and 0.7 nmol/L (0.6–0.7 nmol/L) when measured with the 
Elecsys® second-generation immunoassay and LC-MS/
MS, respectively.
Absolute differences in testosterone concentrations 
were highest during the first days after birth (Figure 1). 
Differences of up to 5.4 and 5.7 nmol/L in boys and girls, 
respectively, were found when the Architect® second- 
generation immunoassay was compared to LC-MS/MS. 
Differences of up to 12.8 and 12.2  nmol/L were found in 
boys and girls, respectively, when the Elecsys® second-
generation immunoassay was compared to LC-MS/MS.
Pooled plasma samples from male (day 0, day 1, 
day 2 and >6  months) and female (day 0–1, day 2 and 
>6  months) infants were analyzed using the ACQUITY 
UPC2-MS/MS (Waters Corporation Milford, USA) for meas-
urement of 11β-hydroxytestosterone as described previ-
ously [8]. In boys, 11β-hydroxytestosterone concentration 
at birth (day 0) was 5.4 nmol/L, declining to levels below 
the LOQ (4.8 nmol/L) from day 1 on. In girls, these concen-
trations were negligible in all samples.
The presented data clearly show that second- 
generation immunoassays overestimate testosterone con-
centrations in newborns, particularly in the first days after 
birth, when compared to LC-MS/MS.
Although the present data should be interpreted 
with caution due to the low sample size, the course of 
testosterone concentrations measured with LC-MS/MS in 
boys is consistent with previous publications [4, 9, 10]. 
In boys, testosterone concentrations were high at birth, 
rapidly decreased to <1 nmol/L within the first few days, 
Table 1: Median and absolute range of plasma testosterone concentrations (nmol/L) measured with a second-generation immunoassay 
 (Architect®) and LC-MS/MS in male and female neonates between 0 days and 6 months of age.
Age, days Boys Girls
n Second-generation
immunoassay
LC-MS/MS n Second-generation
immunoassay
LC-MS/MS
0 3 5.0 (4.0–13.5) 4.8 (1.3–8.7) 2 3.8 (2.2–5.4) 0.2 (0.1–0.3)
1 4 7.0 (2.1–9.0) 3.7 (1.1–7.3) 3 3.1 (1.5–5.8) 0.3 (0.1–0.3)
2 3 4.1 (2.4–4.5) 1.9 (1.7–2.1) 3 1.6 (0.7–2.3) 0.1 (0.1–0.2)
3–4 3 1.5 (1.4–1.5) 0.7 (0.4–0.9) 9 1.1 (0.3–2.7) 0.1 (0.1–0.5)
5–7 6 1.4 (0.8–2.1) 0.4 (0.2–1.2) 8 0.8 (0.2–1.2) 0.2 (0.1–0.3)
8–30 4 5.9 (4.9–7.6) 6.4 (4.7–7.5) 14 0.8 (0.3–2.2) 0.2 (0.1–0.4)
31–120 6 4.3 (2.7–9.4) 5.0 (1.7–7.8) 3 0.4 (0.1–0.6) 0.1 (0.1–0.2)
121–180 4 0.4 (0.2–1.4) 0.5 (0.2–1.6) 3 0.2 (0.1–0.2) 0.1 (0.05–0.1)
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Figure 1: Absolute differences in testosterone concentrations 
(nmol/L) between LC-MS/MS and immunoassays in boys (open 
icons) and girls (closed icons).
Testosterone was measured with two second-generation immunoas-
says (Architect [Abbott Diagnostics] [◊] and Elecsys [Roche diag-
nostics] [□]) and LC-MS/MS in male and female neonates between 
0 days and 6 months of age.
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followed by a rise starting from the second week with a 
peak around age 1–3  months, with a subsequent fall to 
prepubertal levels. In girls, testosterone concentrations 
are consistently low when measured with LC-MS/MS. By 
contrast, measurements with second-generation immu-
noassays show relatively high testosterone concentra-
tions in the first days after birth. These high postnatal 
testosterone concentrations in girls have also been pub-
lished previously when measured with direct immunoas-
says [4, 9, 10].
In both boys and girls, higher testosterone concentra-
tions were found when measured with both widely used 
second-generation immunoassays compared to LC-MS/
MS, mainly in the first days after birth.
Positive interference due to cross-reactivity with 
other steroids is a known problem for immunoassays [2], 
especially in neonatal samples [3, 4]. These publications 
report that purification and extraction steps should be 
performed before measurement with traditional radio-
immunoassays. However, despite these purification steps, 
the published postnatal testosterone concentrations in 
girls are still higher compared to our present findings as 
determined with LC-MS/MS [4, 9, 10].
The precise nature of the interfering compounds in 
neonates has yet to be elucidated. We additionally ana-
lyzed 11β-hydroxytestosterone levels because this metabo-
lite has been shown to have a cross-reactivity of 30.6% and 
18.0% in the Architect® and Elecsys® second-generation 
immunoassays, respectively, as reported by the manufac-
turer. In boys, the cross-reactivity may partly be explained 
by the 11β-hydroxytestosterone levels measured at day 0. 
However, in girls, levels of this steroid were negligible. It 
can therefore be concluded that other interfering metabo-
lites in girls, and also in boys, remain unknown.
In cases of DSD, it is of utmost importance that gender 
assignment is based on accurate measurements of tes-
tosterone, which can be performed within the first few 
days after birth. Within this period, a clear discrimina-
tion between boys and girls can only be made when using 
LC-MS/MS.
In conclusion, even when using the second- generation 
immunoassays, falsely high testosterone concentra-
tions are measured in neonates during the first weeks 
after birth, which could lead to diagnostic confusion. An 
LC-MS/MS method should therefore be used to accurately 
determine testosterone concentrations in neonates in the 
first month of life.
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